- Home
- TSHA
as of 01-28-2026 2:58pm EST
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 1.5B | IPO Year: | 2020 |
| Target Price: | $10.56 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $6.02 | Next Earning Date: | 02-25-2026 |
| Revenue: | $6,310,000 | Revenue Growth: | -36.36% |
| Revenue Growth (this year): | -20.4% | Revenue Growth (next year): | -33.85% |
AI-Powered TSHA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Taysha Gene Therapies Inc. (TSHA)
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$4.61
Shares
23,849
Total Value
$109,943.89
Owned After
1,443,786
SEC Form 4
President and Head of R&D
Avg Cost/Share
$4.61
Shares
26,918
Total Value
$124,091.98
Owned After
1,317,389
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$4.61
Shares
41,312
Total Value
$190,448.32
Owned After
2,908,257
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$4.75
Shares
78,968
Total Value
$375,098.00
Owned After
1,443,786
SEC Form 4
President and Head of R&D
Avg Cost/Share
$4.75
Shares
89,132
Total Value
$423,377.00
Owned After
1,317,389
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$4.75
Shares
136,789
Total Value
$649,747.75
Owned After
2,908,257
SEC Form 4
President and Head of R&D
Avg Cost/Share
$4.71
Shares
200,000
Total Value
$942,000.00
Owned After
1,317,389
SEC Form 4
President and Head of R&D
Avg Cost/Share
$4.51
Shares
260,047
Total Value
$1,172,811.97
Owned After
1,317,389
SEC Form 4
President and Head of R&D
Avg Cost/Share
$4.75
Shares
110,125
Total Value
$523,093.75
Owned After
1,317,389
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Alam Kamran | TSHA | CHIEF FINANCIAL OFFICER | Jan 26, 2026 | Sell | $4.61 | 23,849 | $109,943.89 | 1,443,786 | |
| Nagendran Sukumar | TSHA | President and Head of R&D | Jan 26, 2026 | Sell | $4.61 | 26,918 | $124,091.98 | 1,317,389 | |
| Nolan Sean P. | TSHA | Chief Executive Officer | Jan 26, 2026 | Sell | $4.61 | 41,312 | $190,448.32 | 2,908,257 | |
| Alam Kamran | TSHA | CHIEF FINANCIAL OFFICER | Jan 23, 2026 | Sell | $4.75 | 78,968 | $375,098.00 | 1,443,786 | |
| Nagendran Sukumar | TSHA | President and Head of R&D | Jan 23, 2026 | Sell | $4.75 | 89,132 | $423,377.00 | 1,317,389 | |
| Nolan Sean P. | TSHA | Chief Executive Officer | Jan 23, 2026 | Sell | $4.75 | 136,789 | $649,747.75 | 2,908,257 | |
| Nagendran Sukumar | TSHA | President and Head of R&D | Jan 12, 2026 | Sell | $4.71 | 200,000 | $942,000.00 | 1,317,389 | |
| Nagendran Sukumar | TSHA | President and Head of R&D | Dec 1, 2025 | Sell | $4.51 | 260,047 | $1,172,811.97 | 1,317,389 | |
| Nagendran Sukumar | TSHA | President and Head of R&D | Nov 28, 2025 | Sell | $4.75 | 110,125 | $523,093.75 | 1,317,389 |
Compare TSHA vs Leading Stocks
See how TSHA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TSHA Taysha Gene Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.